Assessment of the efficacy of an attenuated live marker classical swine fever vaccine (Flc-LOM-BErns) in pregnant sows. Issue 27 (12th June 2019)

• Record Type: Journal Article
• Authors: Lim, Seong-in; Choe, SeEun; Kim, Ki-Sun; Jeoung, Hye-Young; Cha, Ra Mi; Park, Gil-Soon; Shin, Jihye; Park, Gyu-Nam; Cho, In-Soo; Song, Jae-Young; Hyun, Bang-Hun; Park, Bong-Kyun; An, Dong-Jun
• Is Part Of: Vaccine. Volume 37:Issue 27(2019)
• Page Start: 3598
• Page End: 3604
• Publication Date: 2019-06-12
• Subjects: Classical swine fever virus -- Flc-LOM-BErns -- Transplacental transmission -- Pregnant sow -- Erns ELSIA; BVDV bovine viral diarrhoea virus -- CPE cytopathic effects -- CSF classical swine fever -- DIVA differentiating infected from vaccinated animals -- END exaltation of Newcastle disease -- DPI days post-infection -- ICS immunocytochemical staining -- NDV Newcastle disease virus -- nt nucleotide -- OIE World Organisation for Animal Health -- qRT-PCR real time polymerase chain reaction -- SNT serological neutralisation antibody test -- ST swine testicular cell -- TCID50 50% tissue culture infective dose -- WPV weeks post-vaccination -- 5′ UTR 5′ untranslated region; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2019.04.076
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: The Flc-LOM-BE rns is live attenuated DIVA vaccine for CSFV. The Flc-LOM-BE rns vaccine protected foetuses from vertical transmission. The Flc-LOM-BE rns vaccine enables differential identification of serum antibodies. Abstract: Here, we constructed an attenuated live marker classical swine fever (CSF) vaccine (Flc-LOM-BE rns ) to eradicate CSF. This was done by taking infectious clone Flc-LOM, which is based on an attenuated live CSF vaccine virus (LOM strain), and removing the full-length classical swine fever virus (CSFV) E rns sequences and the 3′ end (52 base pairs) of the CSFV capsid. These regions were substituted with the full-length bovine viral diarrhoea virus (BVDV) E rns gene sequence and the 3′ end (52 base pairs) of the BVDV capsid gene. Sows were vaccinated with the Flc-LOM-BE rns vaccine 3 weeks before insemination and then challenged with virulent CSFV at the early, mid- or late stages of pregnancy. We then examined transplacental transmission to the foetuses. Piglets born to sows vaccinated with Flc-LOM-BE rns did not show vertical infection, regardless of challenge time. In addition, CSFV challenge did not affect the delivery date, weight or length of the foetus. Pregnant sows inoculated with the Flc-LOM-BE rns vaccine were anti-CSF E rns antibody-negative and anti-BVDV E rns antibody-positive. Challenge of pregnant sows with virulent CSFV resulted in anti-CSF E rns antibody positivity. These results strongly indicate that differential diagnosis can be conducted between the Flc-LOM-BE rns vaccinated animal and virulent CSFV affected animal by detecting antibody against BVDV E rns or CSF E rns gene. Therefore, the Flc-LOM-BE rns vaccine may fulfil the function of differential diagnosis which required for DIVA vaccine.